Fig. 2.

Structures of first, second, and third generation of EGFR TKIs and their respective initial FDA approval dates. The second and third generation inhibitors are irreversible inhibitors with their responsible covalent warheads highlighted in red. The unique C5-substituent responsible for mobocertinib (6)’s specificity is highlighted in blue